Biographical Sketch:
Dr. Chase’s research focused on the pathogenesis and treatment of Parkinson’s disease and related neurodegenerative disorders. In early 2005 Dr. Chase joined Hamilton Pharmaceuticals as CEO, president and a director, where he raised 11M in venture capital and advanced the development of its pioneering lead product. Upon Hamilton’s acquisition by publicly-traded pharmaceutical company in 2007, he founded the Chase Pharmaceuticals Corporation.
He is a graduate of the Sloan School of Management at the Massachusetts Institute of Technology and of the School of Medicine at Yale University. He completed neurology residency training at Harvard Medical School and the Massachusetts General Hospital.
Dr. Chase then received postdoctoral training in basic and clinical neuropharmacology at the National Institute of Mental Health (NIMH) before transferring to the National Institute of Neurological Disorders and Stroke. While at the NINDS, Dr. Chase served as Scientific Director, Intramural Director, Clinical Director and founding Chief of the Experimental Therapeutics Branch. He received both the Superior and the Distinguished Service Medals from the U.S. Public Health Service as well as awards from Yale University and the Johann Wolfgang Goethe University of Frankfurt, the American Parkinson’s Disease Association, National Parkinson Foundation, American Academy of Neurology, Movement Disorders Society, and the governments of Bolivia and Pakistan.
He served as principal investigator on nearly 200 clinical trials, published more than 500 peer-reviewed papers and contributed to the development of several major drugs used in the treatment of these disorders.
Topical Index:
Interview History:
Dates: 03-Dec
Interviewer: T.Ban
Transcript:
Papers: